Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Joe Raedle/Getty Images
Bayer announced plans on Thursday to sell multiple assets, including its animal health unit, sunscreen brand Coppertone, foot-care brand Dr. Scholl's and its majority stake in German chemical park operator Currenta. It also will cut 10% of its workforce, representing around 12,000 jobs.
Why it matters: It's an admission that Bayer bit off more than it could chew when it paid $14 billion to buy Merck in 2014 and another $63 billion to buy Monsanto earlier this year. And it's yet another conglomerate eager to shrink its footprint. "Bayer seems to have flunked its due diligence twice," write Stephen Wilmot and Charley Grant for the Wall Street Journal.